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Indoxyl sulfate (IS) accumulation occurs early during chronic kidney disease (CKD) progression and contributes to renal
dysfunction by inducing fibrosis, inflammation, oxidative stress, and tissue remodeling. Renal toxicity of high IS concentrations
(250 μM) has been widely explored, particularly in resident tubular and glomerular cells, while the effect of a moderate IS
increase on kidneys is still mostly unknown. To define the effects of IS accumulation on renal fibroblasts, we first analyzed
kidneys of C57BL/6 mice receiving IS (0.1%) in drinking water for 12 weeks. As a next step, we treated renal fibroblasts
(NRK-49F) with IS (20 μM) with or without the HSP90 inhibitor 17-AAG (1 μM). In mouse kidneys, IS increased the collagen
deposition and HSP90 and α-SMA expression (immunohistochemistry) in interstitial fibroblasts and caused tubular necrosis
(histological H&E and picrosirius red staining). In NRK-49F cells, IS induced MCP1, TGF-β, collagen I, α-SMA, and HSP90
gene/protein expression and Smad2/3 pathway activation. IS had no effects on fibroblast proliferation and ROS production.
17-AAG counteracted IS-induced MCP1, TGF-β, collagen I, and α-SMA expression and Smad2/3 phosphorylation. Our study
demonstrates that the IS increase promotes renal fibroblast activation by a HSP90-dependent pathway and indicates HSP90
inhibition as a potential strategy to restrain IS-induced kidney inflammation and fibrosis in CKD.
1. Introduction
In patients with chronic kidney disease (CKD), the progres-
sive decline of the glomerular filtration rate (GFR) and kid-
ney metabolic function hinders the removal of several
endogenous toxins which are normally cleared by the kidney.
A current hypothesis is that these toxic compounds, accumu-
lating in blood and tissues, become triggers for CKD progres-
sion and contribute to CKD-related complications.
Indoxyl sulfate (IS) has been extensively studied as a
putative uremic toxin [1, 2]. Circulating IS increases rather
precociously in CKD patients [3] and reaches very high
plasma levels in patients with stage 5-5D CKD, exceeding
500μM/l as compared to 0.1–2.39μM/L in the healthy popu-
lation [4]. Remarkably, previous in vitro observations reveal
that even a moderate increase in IS affects cell homeostasis
and induces tissue remodeling [5], and several clinical studies
point out that IS levels predict the progression of CKD [6].
Renal toxicity of high IS concentrations (exceeding
250μM) has been widely explored, in particular in resident
tubular and glomerular cells. Both in proximal tubule cells
and in podocytes [7], IS has profibrotic [8], prooxidant [9],
and proinflammatory [10] action, while the effect of a mod-
erate increase in circulating IS levels in kidneys is far to be
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defined. Renal fibrosis is a common adaptive response to a
variety of pathological triggers, and fibroblast activation in
the kidney contributes to tissue remodeling by collagen pro-
duction and release of profibrotic factors [11], being involved
in the activation of multiple pathways which include the
TGF-β and the Smad downward signaling [12].
Heat shock proteins (HSPs) are a family of molecular
chaperone proteins; among them, HSP90 is one of the most
abundant and is involved in protein folding and stabilization
[13]. Various stressful conditions induce the activation of
HSP90, which has been found to be upregulated during the
ischemia-reperfusion injury in the kidney [14] and in models
of dermal [15] and pulmonary fibrosis [16]. IS is a ligand of
the aryl hydrocarbon receptor (AhR); upon binding, IS and
AhR form a complex with HSP90, which translocates to the
nucleus and promotes proinflammatory and fibrotic target
gene transcription.
In this paper, we initially observed the effect of IS supple-
mentation on kidney histology, HSP90 expression, and fibro-
blast phenotype in mice. Next, we characterized in vitro the
effects of 20μM IS, a concentration found in early stages of
CKD, on the renal fibroblast phenotype and inflammatory
profile through activation of Smad 2/3 and HSP90. Finally,
we demonstrated that pretreatment with 17-N-allylamino-
17demethoxygeldanamycin (17-AAG), a selective HSP90
inhibitor, is able to reverse the IS-induced fibroblast activa-
tion, suggesting HSP90 inhibition as an option to restrain
fibrosis in kidneys during CKD progression.
2. Materials and Methods
2.1. Animal Model.Male C57BL/6 mice (bred in-house from
stock originally obtained from Harlan Laboratories, S. Pietro
al Natisone, UD, Italy), 8 to 12 weeks old, were housed in a
pathogen-free environment. Water and regular mouse diet
were available ad libitum. Two separate groups were used
to acquire data: the IS group (IS, N = 6), receiving 0.1% IS
in drinking water, and the control group (CTR, N = 6).
Water consumption was recorded every second day, when
replacing the IS solution, and the body weight weekly. The
study lasted for 12 weeks (Supplementary 1, Figure 1A). At
the termination of the in vivo study, mice were killed in
a CO2 chamber. Immediately after explantation, kidneys
were dissected and kept in cold PBS for 40 minutes,
changing the buffer solution 3 times, and then fixed in cold
2% paraformaldehyde.
2.2. Histopathological Examination and Fibrosis
Quantification. Standard histopathological techniques were
followed for processing the fixed kidney tissue and the prep-
aration of paraffin blocks. Hematoxylin and eosin (H&E)
staining was performed to detect tissue damage and tubular
necrosis. Specimens were examined in a blinded manner by
two pathologists independently under light microscopy.
Briefly, six high-power fields (40x magnification) were
checked for confluent cell necrosis or sloughing of the tubu-
lar epithelium and loss of nuclei and of cytoplasm (evidenced
as light areas), as described by Speir and colleagues [17].
Picrosirius red staining was performed to quantify colla-
gen deposition. The paraffin sectionswere dewaxed, hydrated,
and stained with a picrosirius red solution (0.1% sirius red
F3B in saturated picric acid) for 1 h, washed twice in acidified
water, and counterstained with Carazzi’s hematoxylin.
2.3. Immunohistochemistry. Paraffin sections (5μm) of 2%
paraformaldehyde-fixed tissue were analyzed for an HSP90
and nitrotyrosine mouse monoclonal antibody (Santa Cruz
Biotechnology, Dallas, Texas, USA) and α-SMA mouse
monoclonal antibody (Dako Agilent Pathology Solution,
Santa Clara, USA). Immunostaining was performed as
described previously [18].
2.4. Cell Cultures and Treatments. Rat kidney fibroblast cells
(NRK-49F) were obtained from the American Type Culture
Collection (ATCC, Carlsbad, California, USA). NRK-49F
cells were maintained in DMEM (EuroClone, Milan, Italy)
containing 2mmol L-glutamine and 100U/mL penicillin-
streptomycin (EuroClone), with 5% FBS, and incubated at
37°C with 5% of CO2.
NRK-49F cells were incubated with 20μM IS, diluted in
ultrapure H2O, for different time lags, depending on the
experimental requirements: the cells were incubated for 15,
30, and 120 minutes to assess the activation of HSP90 and
p- (phospho-) Smad 2/3, for 5 hours to evaluate the mRNA
levels of MCP1, TGF-β, and collagen I, for 1, 3, and 16 hours
to evaluate the mRNA levels of NOX4, and for 24 hours to
evaluate α-SMA and collagen I protein expression. Finally,
fibroblasts were treated with 20μM IS for 60 minutes to
assess the ROS production and for 24 and 48 hours to analyze
the cell proliferation. In selected experiments, 1μM HSP90
inhibitor (tanespimycin (17-AAG); Selleckchem, Munich,
Germany) was added to the culture medium 1 hour before
stimulation with IS.
2.5. mRNA Analysis. The total RNA was extracted using the
QIAzol Lysis Reagent (Qiagen Sciences, Maryland, USA),
and the concentration and integrity of each sample were
evaluated on a NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies Inc., Wilmington, DE, USA). 1μg
RNA was used for cDNA synthesis.
2.6. cDNA Reverse Transcription and Quantitative Real-Time
PCR. cDNA synthesis was performed using the iScript™
cDNA synthesis kit RT (Bio-Rad Laboratories Inc., Hercules,
California, USA). MCP1, TGF-β, collagen I, NOX4, and
GAPDH primers were obtained from Tib Molbiol Srl
(Genoa, Italy), and sequences are reported in Table 1. PCR
amplification was carried out in a total volume of 10μl,
containing 1μl of cDNA solution, 5μl of SYBR Master Mix
solution (Eppendorf, Hamburg, Germany), 0.03μl of each
primer, and 3.94μl of nuclease-free water. GAPDH was
quantified and used for the normalization of expression
values of the other genes. Fluorescence signals measured
during the amplification were considered positive if the
fluorescence intensity was more than 20-fold greater than
the standard deviation of the baseline fluorescence. The
∆∆CT method of relative quantification was used to deter-
mine the fold change in expression. Assays were run in
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triplicate using Universal PCRMaster Mix on aMasterCycler
RealPlex (Eppendorf) PCR system.
2.7. Proliferation and ROS Production. Proliferation was eval-
uated by cell labeling with carboxyfluorescein succinimidyl
ester (CFDA-SE; Invitrogen, Carlsbad, California, USA).
Data were analyzed with the Proliferation Wizard module
of the ModFit LT 4.0 software (Verity Software House,
Topsham, ME, USA), and the results were expressed as the
proliferation index.
Intracellular ROS production was evaluated using the
CellROX Deep Red kit from Life Technologies (Carlsbad,
California, USA). Following treatments, a CellROX reagent
was added for 30 minutes. Cells were directly analyzed on
FACSCanto II.
2.8. Western Blot Analysis. Cells were lysed in cold buffer
(20mM HEPES, 150mM NaCl, 10% (v/v) glycerol, 0.5%
(v/v) NP-40, 1mM EDTA, 2.5mM DTT, 10μg/l aprotinin,
leupeptin, pepstatin A, 1mM PMSF, and Na3VO4). Protein
concentration was determined by using the Pierce BCA
Protein Assay Kit (Thermo Fisher Scientific; Rockford, IL,
USA), and 10–20μg was resolved on SDS-polyacrylamide
gels and electrotransferred to a PVDF membrane (Merck
Group). Blots were probed using an anti-HSP90 (AC88)
monoclonal antibody (Santa Cruz Biotechnology), anti-p-
SMAD 2 (Ser 465/467) polyclonal antibody (Cell Signaling
Technology; Danvers, USA), anti-p-SMAD 3 (Ser 423/425)
monoclonal antibody (Cell Signaling Technology), anti-α-
SMA monoclonal antibody (Dako Agilent Pathology
Solution; Santa Clara, CA, USA), anti-TGF-β monoclonal
antibody (Santa Cruz Biotechnology), and anti-CCL2/MCP1
polyclonal antibody (Novus Biologicals). The reference pro-
teins were detected with an anti-β-actin mouse monoclonal
antibody (Santa Cruz Biotechnology), anti-Smad rabbit poly-
clonal antibody (Cell Signaling Technology), or anti-histone
3 rabbit polyclonal antibody (Cell Signaling Technology)
and incubated with horseradish peroxidase secondary anti-
bodies (Cell Signaling Technology). Immunoblots were
developed with the Immobilon Western Chemiluminescent
HRP Substrate (Merck Group, Darmstadt, Germany). Band
intensities were determined using the Alliance system
(Uvitec; Cambridge, UK).
2.9. Immunocytochemistry and Immunofluorescence. NRK-
49F cells were grown on chamber slides to subconfluence,
treated with IS with or without 17-AAG and fixed in cold
methanol. For immunocytochemistry, after a 24-hour treat-
ment, fixed cells had undergone quenching of the endogenous
peroxidase with H2O2 in PBS and incubation with an anti-
collagen I polyclonal antibody (Proteintech; Manchester,
UK) and with an anti-α-SMA monoclonal antibody (Dako
Agilent Pathology Solution); immunostaining was then per-
formed as previously described [19]. For immunofluores-
cence, treatments lasted for 15, 45, and 120min. Cells were
incubated with an anti-HSP90 monoclonal antibody (AC88,
Santa Cruz Biotechnology) and then with the secondary
anti-mouse antibody goat-anti-mouse Alexa Fluor 488 (Invi-
trogen, Carlsbad, CA, USA).
2.10. Image Analysis. In immunohistochemical/immunocy-
tochemical staining, the positivity was evaluated by image
analysis performed using the Leica Q500 MC Image Analysis
System (Leica, Cambridge, UK) as previously described [18].
For picrosirius red staining, a total of 10 fields were randomly
chosen per mouse and images were viewed with brightfield
illumination as well as with polarization contrast illumina-
tion at 40x. Picrosirius red is a birefringent molecule that
binds to collagens. The complex fibrillar collagen/sirius red
can be detected under polarized light, and the collagen
bundles are red, yellow, and green. Collagen expression was
quantified under brightfield illumination.
2.11. Statistics. In vitro experiments were performed at least 3
times. Summary data are expressed as mean ± SEM and
compared by Student’s t-test. Statistical significance was set
at p < 0 05. All statistical analyses were performed using
GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, California, USA).
3. Results
3.1. IS Induces Fibrosis and HSP90 Activation in Mice. Kid-
neys of C57BL/6 mice receiving continuous supplementation
of 0.1% IS in drinking water displayed signs of tubular necro-
sis (Figure 1(a)) and interstitial fibrosis whose severity was
evaluated by picrosirius red staining (Figure 1(b)). As shown
in Figure 1(b), a significant increase in staining intensity was
noticeable in the interstitial zone of kidneys obtained from
IS-treated mice (3 fold in respect top untreated control mice,
p < 0 01). α-SMA expression in the interstitium is associated
with the progression of kidney disease, and the accumulation
of α-SMA-positive fibroblasts represents the earliest histolog-
ical marker of fibrosis progression [20]. We found a signifi-
cant increase in α-SMA protein in interstitial fibroblasts
(2-fold vs. control mice, p < 0 05) (Figure 1(c)) and upreg-
ulation of HSP90 in the tubular-interstitial compartment
(1.4-fold increase vs. control mice, p < 0 05) (Figure 1(d)).
Table 1: Primer sequences.
Name Species Accession number Forward Reverse
GAPDH Rat NM_017008.4 ctctctgctcctccctgttct atacggccaaatccgttcaca
Collagen I Rat NM_053304.1 tcacctacagcacgcttg ggtctgtttccagggttg
TGF-β Rat NM_021578.2 tggaagtggatccacgcgcccaagg gcaggagcgcacgatcatgttggac
MCP1 Rat NM_031530.1 cagttaatgccccactcacct tgacaaatactacagcttctttggg
NOX4 Rat NM_053524.1 gatgactggaaaccatacaagctaag catagagcaagtctgcaaaccaactg
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These data revealed that even moderate IS increases may
induce HSP90 overexpression and prime interstitial fibro-
blasts to an activated phenotype.
3.2. IS Induces a Profibrotic and Proinflammatory Phenotype
in NRK49F Cells. Next, we examined the effects of 20μM IS
on the profibrotic and proinflammatory phenotype in the
NRK-49F cell line.
Both collagen I mRNA and protein were increased 3-fold
(p < 0 05 and 0.001, respectively) (Figure 2(a)), and α-SMA
protein level arose significantly, as shown by western blot
analysis and immunocytochemistry (Figure 2(b): 9.5-fold,
p < 0 01), in respect to untreated control cells.
IS also induced expression of TGF-β (Figure 2(c):
2.8-fold for mRNA and 2-fold for protein expression vs.
untreated cells; p < 0 05 and 0.01, respectively), a potent
mediator in renal fibrosis, and MCP1, one of the inflamma-
tory cytokines involved in tubular-interstitial injury (3-fold
for mRNA and 1.5-fold for protein expression vs. untreated
cells, p < 0 05) (Figure 2(d)).
3.3. IS Does Not Stimulate Proliferation and Oxidative Stress
in NRK49 Cells. Proliferation of fibroblasts and oxidative
stress are critical pathological processes during initiation
and maintenance of fibrotic lesions; however, in our experi-
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(d)
Figure 1: Mouse kidney analysis after a 12-week exposure to 0.1% IS. (a) H&E staining; arrows indicate areas of tubular necrosis. (b) Collagen
deposition as revealed by picrosirius red staining, brightfield illumination (left side) and polarization contrast illumination (right side); the
graph represents the quantification of red staining intensity under brightfield illumination. (c, d) Images of immunochemistry of α-SMA
and HSP90; boxes specify the positive nuclei of interstitial fibroblasts found in the kidney from IS-treated mice. The histograms indicate
the immunopositivity quantification (fold change: FC). (magnification: (a)–(c), ×400; (d), ×1000); ∗p < 0 05.
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proliferation rate neither the redox status as revealed by ROS
production (Figure 2(e)) and NOX4 mRNA (Supplementary
2, Figure 2).
3.4. Effects of IS on Cell Signaling. To confirm our observation
on mouse kidneys, we verified in NRK-49F cells the effects of
IS on HSP90 activation. IS induced a 70% increase in HSP90
protein expression after a 15-minute treatment; this increase
in respect to the control level lasted 2 hours (p < 0 01-0.05 vs.
baseline referred to as T0) (Figure 3(a)). By looking at the
intracellular distribution, a marked perinuclear concentra-
tion of HSP90 was noticeable already after a 15-minute IS
treatment (Figure 3(b)); looking at the downstream signaling,
we examined the effects of IS on the Smad pathway
(Figure 4). Both Smad 2 and Smad 3 are activated in respect
to T0 after 120 minutes (p < 0 05 and p < 0 001, respectively)
with Smad 3 phosphorylation occurring early within 15
minutes (p < 0 01).
3.5. Effects of HSP90 Inhibition on the Profibrotic and
Proinflammatory Phenotype. We next examined the effects
of IS treatment in the presence of 1μM 17-AAG, a selective
inhibitor of HSP90. 17-AAG counteracted the increase in
mRNA and protein collagen I synthesis (-70 and -80%,
respectively, p < 0 05-0.001) (Figure 5(a)) and in α-SMA
protein expression (p < 0 05) as depicted in Figure 5(b).
The inhibition of HSP90 also blunted TGF-β and MCP1
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(e)
Figure 2: Effects of IS on the NRK-49F rat kidney fibroblast cell line. (a) Collagen I mRNA and protein in IS-treated and untreated NRK-49F
cells. Data are expressed as fold change FC ± SEM versus untreated cells (∗p < 0 05 and ∗∗∗p < 0 001, respectively). Photos are representative
of collagen I expression and pattern evaluated by immunocytochemistry (magnification ×400). (b) α-SMA protein expression in IS-treated
and untreated NRK-49F cells. Data, obtained by western blot analysis, are expressed as fold change FC ± SEM versus untreated cells
(∗∗p < 0 01). Pictures are representative of α-SMA expression evaluated by western blot and immunocytochemistry. (c) TGF-β and (d)
MCP1 mRNA and protein levels in IS-treated or untreated NRK-49F cells. mRNA expression is evaluated by real-time PCR, normalized
for GAPDH mRNA. Western blot analysis is normalized for β-actin; values are expressed as fold increase ± SEM versus untreated cells
(∗p < 0 05). (e) Flow cytometry analysis of the proliferation index, after 48 hours of exposure, and ROS production, after 60 minutes of
exposure, as detected by the probes CFSE and CellRox, respectively, in NRK-49F cells treated or not with 20μM IS. UC: untreated cells;
IS: indoxyl sulfate-treated cells.
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and -40%, respectively, p < 0 01) (Figures 5(c) and 5(d)).
Lastly, 17-AAG lowered NRK-49F cells proliferation
(p < 0 05 vs. IS-treated cells) (Figure 5(e)).
3.6. 17-AAG Blocks IS-Induced Activation of the Smad
Pathway. We then evaluated the effect of 17-AAG on
HSP90 and Smad 2/3 activation. As shown in Figure 6, the
pretreatment with 17-AAG blocked, stably over time, the
perinuclear and nuclear HSP90 translocation (Figure 6(a))
and the IS-induced phosphorylation of Smad 2/3 (-80%
and -60%, p < 0 05-0.01) (Figure 6(b)).
4. Discussion
The purpose of the present study was essentially to better
understand whether moderate IS levels contribute to renal
fibroblast activation. First, we set up an in vivo experimental
design consisting in a chronic supplementation of moderate
amount of IS to mice with a preserved renal function
(Supplementary 1); then, to buttress our ex vivo observation,
we evaluated in vitro the potential for moderate IS concentra-
tion, such as 20μM, to prime the renal fibroblast phenotype.
Finally, since the cytoplasmic receptor of IS, AhR, is tightly
regulated by the molecular complex with the chaperone
HSP90 [21], we tested whether the profibrotic effects of IS
occur through the HSP90/Smad 2/3 pathway.
Our results highlight that even the modest increase in IS,
administered continuously for 12 weeks, promotes HSP90
upregulation and α-SMA expression, a hallmark of fibroblast
transition from a resting phenotype to an activated pheno-
type, as well as interstitial collagen deposition. When tested
on renal fibroblast cell culture, 20μM IS was able to induce
a profibrotic and proinflammatory phenotype, by upregulat-
ing the TGF-β signal and collagen I synthesis. We also
demonstrated that IS-induced fibroblast activation occurs
through the HSP90/Smad 2/3-dependent pathway, as proven
by the efficacy of the HSP90 inhibitor (17-AAG) in inhibiting
IS-induced TGF-β signaling and collagen I synthesis.
Among a variety of uremic toxins, IS is of particular
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Figure 3: Effects of IS on HSP90 after different times of IS exposure (0, 15, 45, and 120min). (a) Total protein expression, evaluated by
western blot, and (b) intracellular localization, detected by immunofluorescence. Arrows indicate perinuclear localization (∗p < 0 05,




























Figure 4: Smad 2 and 3 phosphorylation after different times of IS
exposure (15, 45, and 120min) in respect to untreated cells (T0),
normalized for total Smad 2/3. Measures are represented as fold
changes ± SEM versus untreated cells (∗p < 0 05, ∗∗p < 0 01, and
∗∗∗p < 0 001).
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and it is hardly removed by conventional dialysis due to its
protein-binding capacity [22]. Several studies have demon-
strated that IS, at uremic concentration (100–500μM),
exerts profibrotic and proinflammatory effects on mesangial
[23] and tubular cells [24] and induces epithelial-to-
mesenchymal transition in NRK-52E renal proximal tubu-
lar cells [25].
Previous animal models on mice and rats were aimed at
obtaining the features of a severe renal failure, which include
the accumulation of not only IS but also other endogenous
compounds [26, 27]; although these models are useful
experimental tools to understand the mechanism operating
in the uremic condition, they cannot be suggestive when
considering a progressive accumulation of IS for small,
chronic intake, as occurs in the first stages of the renal disease.
So far, IS has been scarcely investigated in relation to
renal fibroblasts and, mostly, when considering moderate IS
increases, as those utilized in our experimental setting and
found during transition from early to moderate kidney dam-
age [28]. These few studies demonstrate that the exposure to
1-5mg/lt IS can induce inflammation in renal tubular cells
[29] and kidney tissue remodeling through binding and acti-
vation of the renal EGF receptor [30]. On this regard, we
believe that our animal and in vitro experimental design
might offer a good platform to investigate its contribution













































































































































































































































































Figure 5: Effects of HSP90 inhibition on the profibrotic and proinflammatory phenotype of NRK-49F cells. (a) Collagen I mRNA and protein
levels and representative images (magnification 400x). The protein expression is evaluated by immunocytochemistry, as shown in the
pictures. Values are expressed as fold changes ± SEM versus cells treated with IS. (b) Western blot and immunocytochemistry for α-SMA
protein expression. The graph reports the measure obtained from western blot analysis. (c) TGF-β and (d) MCP1 mRNA and protein
expression. (e) Proliferation index of IS and 17-AAG+IS cells vs. untreated cells (∗p < 0 05, ∗∗∗p < 0 001). mRNA expression is tested by
real-time PCR and normalized to GAPDH mRNA. UC: untreated cells; IS: indoxyl sulfate-treated cells; 17-AAG+IS: cells pretreated with
the HSP90 inhibitor 17-AAG and then treated with IS.
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failure, may lead to increased level of circulating IS, such as
gut microbiota disequilibrium, reduced plasma albumin,
and unbalanced IS/albumin ratio for binding competition
with other uremic compounds [31].
In the pathogenesis of CKD, resident fibroblasts are
key players and renal interstitial fibrosis is considered the
hallmark of progressive renal disease. Several studies demon-
strate that renal impairment correlates better with interstitial
changes than with glomerular changes in most forms of
CKD, indicating that renal function is also influenced by
the interstitial cell behavior. In 5/6-nephrectomized uremic
rats, administration of IS upregulated TGF-β, tissue inhibitor
of metalloproteinase-1 (TIMP-1), and proalpha 1(I) collagen
in the renal cortex and provoked a significant decline in renal
function and worsening of renal sclerosis [32].
High IS levels induce ROS production in different cell
types, such as vascular endothelial cells, vascular smooth
muscle cells, renal tubular cells, monocytes, and macro-
phages [33–37]. In our setting, the NOX4 mRNA level and
ROS production are unchanged by IS treatment, indicating
that the IS detrimental effects on our cell line are not induced
by oxidative stress damage. This result is reinforced also by
ex vivo immunostaining of kidneys for nitrotyrosine, a
marker for inflammation and ROS production suitable to
detect oxidative damage: increased positivity is detectable
in kidneys from IS-treated mice and is mainly localized
in tubular cells, while interstitial fibroblasts are negative
(Supplementary 3).
A similar observation was obtained from monocytes
exposed to different IS concentrations: moderate levels of IS
(1-20μM) evoked only a transient rise in ROS production,
but sufficient to promote monocyte differentiation toward a
profibrotic and proinflammatory phenotype [5].
The TGF-β/Smad 2/3-mediated damage has been found
to be operative in several renal fibrotic models [38, 39]
and human nephropathies [40]; in the present study, we
identify the HSP90/Smad 2/3 activation as the pathway of
IS profibrotic induction.
Fibrosis and inflammation constitute a deleterious loop,
and the development of fibrosis with loss of renal function
often follows renal inflammation [41].
The IS proinflammatory effect was shown in several dif-
ferent cell types: endothelial cells [42], adipocytes [43], and
glomerular [23] and renal tubular cells [29]; these studies rec-
ognized IS as an important mediator of cell dysfunction in
promoting a persistent and systemic inflammatory state in
CKD patients. In our experimental setting, we demonstrated
that IS can stimulate MCP1 expression in renal fibroblasts
and identified HSP90 as a possible shared pawn between
IS-induced fibrosis and inflammation in renal fibroblasts.
HSP90 is one of several stress proteins, and as such, its
modulation is a potential therapeutic target under stressful
conditions. Previous studies demonstrated that modulation
of HSP90 affects TGF-β-induced collagen synthesis in der-
mal fibroblasts, [15], attenuates renal fibrosis through degra-
































Figure 6: 17-AAG blocks HSP90-dependent activation of the Smad pathway induced by IS in NRK-49F cells. (a) HSP90 intracellular
localization after a 120-minute IS treatment with or without 17-AAG. Arrows indicate nuclear sites, where no immunopositivity occurred
in the presence of 17-AAG. (b) Western blot of Smad 2/3 phosphorylation in cells treated for 120 minutes with IS, 17-AAG, and 17-AAG
+IS, respectively. Results are normalized for total Smad 2/3. Values are expressed as fold change ± SEM versus cells treated with IS
(∗p < 0 05 and ∗∗p < 0 01). IS: indoxyl sulfate-treated cells; 17-AAG+IS: cells pretreated with the HSP90 inhibitor 17-AAG and then
treated with IS.
8 Oxidative Medicine and Cellular Longevity
tubular cells and in a murine CKD model [44], regulates
the fibroblast activation in pulmonary and hepatic fibrosis
[16, 45], and hampers the inflammatory response in ath-
erosclerosis [46] and in ischemia-reperfusion injury in
the kidney [47].
To date, the link between HSP90 activation/inhibition
and IS effects was scarcely studied. First of all, we have
observed that IS induces HSP90 expression; accordingly, pre-
treatment with 17-AAG blunted Smad 2/3 signaling, inflam-
matory (MCP1) and fibrotic molecule expression (collagen I,
α-SMA, and TGF-β), and proliferation of renal fibroblasts,
suggesting HSP90 activity as a crossroad for IS-induced
inflammation and fibrosis.
In conclusion, our report demonstrates that moderate
levels of IS cause fibrosis and inflammation by upregulating
HSP90 in renal fibroblasts and suggests HSP90 inhibition
as an effective tool for reducing IS-induced damage and
slowing the progression of renal disease.
Data Availability
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available from the corresponding author upon request.
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Supplementary Materials
Supplementary 1. Figure 1: (A) in vivo experimental design,
(B) body weight, and (C) weekly liquid consumption records.
Supplementary 2. Figure 2: the NOX4 mRNA levels are not
modified by 1-hour treatment with IS.
Supplementary 3. Figure 3: immunostaining for nitrotyrosine
to detect oxidative damage in vivo. Images A-B: magnifica-
tion 20x; in image B, white boxes indicate the necrotic
area. Images C-D: magnification 40x; in image D, black
arrows indicate interstitial fibroblasts (negative to the
immunostaining).
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